<![CDATA[<body bgcolor="#FFFFFF" text="#000000">
Glenmark’s three-year work with PDE-4 inhibitors, more specifically with GRC 3886 has helped it create a library of compounds.
This library of compounds has tremendous potential since PDE-4 isoenzymes are expressed very early in the inflammatory pathway in different organ systems of the human body.
The other inflammatory conditions and their therapy areas that Glenmark is working on are:
Therapy Areas
Specific Indications
Musculoskeletal
Rheumatoid Arthritis
Central Nervous System [CNS]
Alzheimer’s Syndrome & Multiple Sclerosis
Dermatology
Atopic Dermatitis
Gastrointestinal
Irritable Bowel Syndrome / Ulcerative Colitis
Ophthalmic
Uveitis
</body>]]>